SILO

Company Overview — What Does Silo Pharma, Inc. Do?

Silo Pharma, Inc. operates as a developmental stage biopharmaceutical company. The company focuses on merging traditional therapeutics with psychedelic research for patients with depression, post-traumatic stress disorder, Alzheimer's, Parkinson's, and other rare neurological disorders. It has a scientific research agreement with the University of Maryland, The Regents of the University of California, and Columbia University. The company was formerly known as Uppercut Brands, Inc. and changed its name to Silo Pharma, Inc. in September 2020. Silo Pharma, Inc. was incorporated in 2010 and is headquartered in Englewood Cliffs, New Jersey. Silo Pharma, Inc. (SILO) is classified as a micro-cap stock in the Consumer Discretionary sector, specifically within the Apparel industry. The company is led by CEO Eric Weisblum and employs approximately 2 people. With a market capitalization of $5M, SILO is one of the notable companies in the Consumer Discretionary sector.

Silo Pharma, Inc. (SILO) Stock Rating — Avoid (April 2026)

As of April 2026, Silo Pharma, Inc. receives a Avoid rating with a composite score of 21.2/100 and 1 out of 5 stars from the Blank Capital Research quantitative model.SILO ranks #4,278 out of 4,446 stocks in our coverage universe. Within the Consumer Discretionary sector, Silo Pharma, Inc. ranks #435 of 445 stocks, placing it in the lower half of its Consumer Discretionary peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

SILO Stock Price and 52-Week Range

Silo Pharma, Inc. (SILO) currently trades at $0.35. The 52-week high for SILO is $1.42, which means the stock is currently trading -75.7% from its annual peak. The 52-week low is $0.22, putting the stock 56.4% above its annual trough. Recent trading volume was 0 shares, suggesting relatively thin trading activity.

Is SILO Overvalued or Undervalued? — Valuation Analysis

Silo Pharma, Inc. (SILO) carries a value factor score of 10/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 0.77x, versus the sector average of 1.94x. The price-to-sales ratio is 41.28x, compared to 0.29x for the average Consumer Discretionary stock.

At current multiples, Silo Pharma, Inc. trades at a premium to most Consumer Discretionary peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

Silo Pharma, Inc. Profitability — ROE, Margins, and Quality Score

Silo Pharma, Inc. (SILO) earns a quality factor score of 20/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -67.8%, compared to the Consumer Discretionary sector average of 5.9%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -56.2% versus the sector average of 2.5%.

On a margin basis, Silo Pharma, Inc. reports gross margins of 56.3%, compared to 36.9% for the sector. The operating margin is -6020.5% (sector: 3.8%). Net profit margin stands at -4729.8%, versus 2.1% for the average Consumer Discretionary stock. Revenue growth is running at 0.0% on a trailing basis, compared to 3.3% for the sector. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

SILO Debt, Balance Sheet, and Financial Health

Silo Pharma, Inc. has a debt-to-equity ratio of 21.0%, compared to the Consumer Discretionary sector average of 91.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. The current ratio is 11.36x, indicating strong short-term liquidity.

SILO has a beta of 1.36, meaning it is more volatile than the broader market — a $10,000 investment in SILO would be expected to move 35.8% more than the S&P 500 on any given day. The stability factor score for Silo Pharma, Inc. is 19/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

Silo Pharma, Inc. Revenue and Earnings History — Quarterly Trend

In TTM 2026, Silo Pharma, Inc. reported revenue of $118,007 and earnings per share (EPS) of $-0.50. Net income for the quarter was $-4M. Gross margin was 56.3%. Operating income came in at $-3M.

In FY 2025, Silo Pharma, Inc. reported revenue of $72,102 and earnings per share (EPS) of $-0.50. Net income for the quarter was $-4M. Gross margin was 38.6%. Revenue grew 0.0% year-over-year compared to FY 2024. Operating income came in at $-4M.

In Q3 2025, Silo Pharma, Inc. reported revenue of $18,025 and earnings per share (EPS) of $-0.12. Net income for the quarter was $-1M. Gross margin was -14.8%. Revenue grew 0.0% year-over-year compared to Q3 2024. Operating income came in at $-1M.

In Q2 2025, Silo Pharma, Inc. reported revenue of $63,931 and earnings per share (EPS) of $-0.19. Net income for the quarter was $-1M. Gross margin was 70.3%. Revenue grew 254.7% year-over-year compared to Q2 2024. Operating income came in at $19,014.

Over the past 8 quarters, Silo Pharma, Inc. has demonstrated a growth trajectory, with revenue expanding from $18,025 to $118,007. Investors analyzing SILO stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

SILO Dividend Yield and Income Analysis

Silo Pharma, Inc. (SILO) does not currently pay a dividend. This is common among smaller companies in the Apparel industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Consumer Discretionary dividend stocks may want to explore other Consumer Discretionary stocks or use the stock screener to filter by dividend yield.

SILO Momentum and Technical Analysis Profile

Silo Pharma, Inc. (SILO) has a momentum factor score of 15/100, signaling weak relative price performance. Stocks with low momentum scores have historically tended to continue underperforming in the near term. The investment factor score is 33/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 50/100 reflects moderate short selling activity.

SILO vs Competitors — Consumer Discretionary Sector Ranking and Peer Comparison

Within the Consumer Discretionary sector, Silo Pharma, Inc. (SILO) ranks #435 out of 445 stocks based on the Blank Capital composite score. This places SILO in the lower half of all Consumer Discretionary stocks in our coverage universe. Key competitors and sector peers include CASEYS GENERAL STORES INC (CASY) with a score of 57.4/100, FIVE BELOW, INC (FIVE) with a score of 51.7/100, TARGET CORP (TGT) with a score of 52.0/100, CARRIAGE SERVICES INC (CSV) with a score of 53.0/100, and PERDOCEO EDUCATION Corp (PRDO) with a score of 51.0/100.

Comparing SILO against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full SILO vs S&P 500 (SPY) comparison to assess how Silo Pharma, Inc. stacks up against the broader market across all factor dimensions.

SILO Next Earnings Date

No upcoming earnings date has been announced for Silo Pharma, Inc. (SILO) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy SILO? — Investment Thesis Summary

The quantitative profile for Silo Pharma, Inc. suggests caution. The quality score of 20/100 flags below-average profitability. The value score of 10/100 indicates premium valuation. Momentum is weak at 15/100, a headwind for near-term performance. High volatility (stability score 19/100) increases portfolio risk.

In summary, Silo Pharma, Inc. (SILO) earns a Avoid rating with a composite score of 21.2/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on SILO stock.

Related Resources for SILO Investors

Explore more research and tools: SILO vs S&P 500 comparison, top Consumer Discretionary stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare SILO head-to-head with peers: SILO vs CASY, SILO vs FIVE, SILO vs TGT.